Detalhe da pesquisa
1.
Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy.
Bioorg Med Chem Lett
; 24(9): 2177-81, 2014 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24685546
2.
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors.
ACS Med Chem Lett
; 12(6): 955-960, 2021 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34141080
3.
Discovery of Novel, Orally Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1.
J Med Chem
; 64(24): 17777-17794, 2021 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34871500
4.
Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase.
Bioorg Med Chem Lett
; 20(9): 2828-31, 2010 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20356737
5.
Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates.
ACS Med Chem Lett
; 8(2): 251-255, 2017 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28197321
6.
Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles.
J Med Chem
; 59(13): 6293-302, 2016 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27366941
7.
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
J Med Chem
; 51(17): 5243-63, 2008 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-18690678